Advertisement

Tumor Biology

, Volume 32, Issue 1, pp 215–222 | Cite as

Genetic polymorphisms of metabolic enzymes—CYP1A1, CYP2D6, GSTM1, and GSTT1, and gastric carcinoma susceptibility

  • Ya-ping Luo
  • Han-chun Chen
  • Md. Asaduzzaman Khan
  • Fang-zhi Chen
  • Xin-xing Wan
  • Bo Tan
  • Fang-dan Ou-Yang
  • Dian-zheng Zhang
Research Article

Abstract

Genetic polymorphisms in metabolic enzymes are associated with numerous cancers. In this study, the relationships between genetic polymorphisms of phase I metabolic enzymes including cytochrome P450 1A1 (CYP1A1), CYP2D6 and phase II metabolic enzymes such as glutathione S-transferase M1 (GSTM1) and GSTT1 and gastric carcinoma susceptibility were investigated. Genomic DNA was isolated from the peripheral blood of 129 healthy controls and 123 gastric carcinoma patients from Han ethnic group of Hunan Province located in Central South China. The genetic polymorphisms of the above mentioned enzymes were analyzed using PCR-RFLP techniques. There was no significant difference among the frequencies of CYP1A1 and/or CYP2D6 gene’s wild type, heterozygous or homozygous mutations between the gastric carcinoma group and control group. But the differences among the frequencies of GSTM1 and GSTT1 null genotype between the gastric carcinoma and control group were significant (both P < 0.05). Also there were significant differences in the frequencies of GSTM1 null in high/high–middle differentiated, middle differentiated, middle–low differentiated and low differentiated gastric tumor separately. GSTM1 null showed an increased risk in middle–low differentiated and low differentiated gastric carcinoma type, but GSTT1 null was not a risk factor for the four pathological types of gastric carcinoma mentioned above. We report here that the genotypes of CYP1A1 and CYP2D6 are not associated with gastric carcinoma risk; GSTM1 null, but not GSTT1 null inheritably increases risk of some pathological types of gastric carcinoma in Han ethnic population of Hunan Province.

Keywords

Cytochrome P450 Glutathione S-transferase Genetic polymorphism Gastric carcinoma 

Notes

Acknowledgments

The work was supported by the grant No. 30371660 from the National Natural Science Foundation of China and the grant CMB No. 99-698 from China Medical Board of New York, Inc.

Conflict of interests

There is no conflict of interests regarding this article.

References

  1. 1.
    Oliveira C, Seruca R, Carneiro F. Genetics, pathology, and clinics of familial gastric cancer. Int J Surg Pathol. 2006;14:21–33.CrossRefPubMedGoogle Scholar
  2. 2.
    Boccia S, Sayed-Tabatabaei FA, Persiani R, Gianfagna F, Rausei S, Arzani D, et al. Polymorphisms in metabolic genes, their combination and interaction with tobacco smoke and alcohol consumption and risk of gastric cancer: a case-control study in an Italian population. BMC Cancer. 2007;7:206–13.CrossRefPubMedGoogle Scholar
  3. 3.
    Medeiros R, Vasconcelos A, Costa S, Pinto D, Ferreira P, Lobo F, et al. Metabolic susceptibility genes and prostate cancer risk in a southern European population: the role of glutathione S-transferases GSTM1, GSTM3, and GSTT1 genetic polymorphisms. Prostate. 2004;58:414–20.CrossRefPubMedGoogle Scholar
  4. 4.
    Agundez JA. Cytochrome P450 gene polymorphism and cancer. Curr Drug Metab. 2004;5:211–24.CrossRefPubMedGoogle Scholar
  5. 5.
    Roberts-Thomson IC, Butler WJ, Ryan P. Meat, metabolic genotypes and risk for colorectal cancer. Eur J Cancer Prev. 1999;8:207–11.CrossRefPubMedGoogle Scholar
  6. 6.
    Androutsopoulos VP, Tsatsakis AM, Spandidos DA. Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer. 2009;9:187–202.CrossRefPubMedGoogle Scholar
  7. 7.
    Chen HC, Hu WX, Liu QX, Li WK, Chen FZ, Rao ZZ, et al. Genetic polymorphisms of metabolic enzymes CYP1A1, CYP2D6, GSTM1 and GSTT1 and leukemia susceptibility. Eur J Cancer Prev. 2008;17:251–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Thuerauf N, Lunkenheimer J. The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants. Eur Arch Psychiatry Clin Neurosci. 2006;256:287–93.CrossRefPubMedGoogle Scholar
  9. 9.
    McLellan RA, Oscarson M, Seidegård J, Evans DA Ingelman-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics. 1997;7:187–91.CrossRefPubMedGoogle Scholar
  10. 10.
    Gaedigk A, Bradford LD, Marcucci KA, Leeder JS. Unique CYP2D6 activity distribution and genotype–phenotype discordance in black Americans. Clin Pharmacol Ther. 2002;72:76–89.CrossRefPubMedGoogle Scholar
  11. 11.
    Yokoi T, Kamataki T. Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese. Pharm Res. 1998;15:517–24.CrossRefPubMedGoogle Scholar
  12. 12.
    Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol. 1994;46:452–9.PubMedGoogle Scholar
  13. 13.
    Douglas KT. Mechanism of action of glutathione-dependent enzymes. Adv Enzymol Relat Areas Mol Biol. 1987;59:103–67.PubMedGoogle Scholar
  14. 14.
    Hosgood HD, Berndt SI, Lan Q. GST genotypes and lung cancer susceptibility in Asian populations with indoor air pollution exposures: a meta-analysis. Mutat Res. 2007;636:134–43.CrossRefPubMedGoogle Scholar
  15. 15.
    Norppa H, Hirvonen A, Jarventaus H, Uuskula M, Tasa G, Ojajarvi A, et al. Role of GSTT1 and GSTM1 genotypes in determining individual sensitivity to sister chromatid exchange induction by diepoxybutane in cultured human lymphocytes. Carcinogenesis. 1995;16:1261–4.CrossRefPubMedGoogle Scholar
  16. 16.
    Bolt HM, Their R. Relevance of the deletion polymorphisms of the glutathione S-transferases GSTT1 and GSTM1 in pharmacology and toxicology. Curr Drug Metab. 2006;7:613–28.CrossRefPubMedGoogle Scholar
  17. 17.
    Clavel J, Bellec S, Rebouissou S, Ménégaux F, Feunteun J, Bonaïti-Pellié C, et al. Childhood leukaemia, polymorphisms of metabolism enzyme genes, and interactions with maternal tobacco, coffee and alcohol consumption during pregnancy. Eur J Cancer Prev. 2005;14:531–40.CrossRefPubMedGoogle Scholar
  18. 18.
    Saadat M. Genetic polymorphisms of glutathione S-transferase T1 (GSTT1) and susceptibility to gastric cancer: a meta-analysis. Cancer Sci. 2006;97:505–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Sung NY, Choi KS, Park EC, Park K, Lee SY, Lee AK, et al. Smoking, alcohol and gastric cancer risk in Korean men: the National Health Insurance Corporation Study. Br J Cancer. 2007;97:700–4.CrossRefPubMedGoogle Scholar
  20. 20.
    Purohit V, Khalsa J, Serrano J. Mechanisms of alcohol-associated cancers: introduction and summary of the symposium. Alcohol. 2005;35:155–60.CrossRefPubMedGoogle Scholar
  21. 21.
    Davis LG, Dibner MD, Battey JF (1986). Preparation of DNA from eukaryotic cells. In: Basic methods in molecular biology. Elsevier, New York, pp 42–50.Google Scholar
  22. 22.
    Hatagima A. Genetic polymorphisms and metabolism of endocrine disruptors in cancer susceptibility. Cad Saúde Pública. 2002;18:357–77.PubMedGoogle Scholar
  23. 23.
    Sinnett D, N’Diaye N, Labuda D, Krajinovic M. Genetic determinants of childhood leukemia. Bull Cancer. 2006;93:857–65.PubMedGoogle Scholar
  24. 24.
    Lao-Sirieix P, Caldas C, Fitzgerald RC. Genetic predisposition to gastro-oesophageal cancer. Curr Opin Genet Dev. 2010;20:210–17.CrossRefPubMedGoogle Scholar
  25. 25.
    Canturk P, Caner V, Oruc N, Akarca US, Tepeli E, Cetin OG, et al. The mRNA expression of cytochrome P450 isoforms in human gastric tissue. Hepatogastroenterology. 2010;57:372–6.PubMedGoogle Scholar
  26. 26.
    Agudo A, Sala N, Pera G, Capellá G, Berenguer A, García N, et al. Polymorphisms in metabolic genes related to tobacco smoke and the risk of gastric cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomark Prev. 2006;15:2427–34.CrossRefGoogle Scholar
  27. 27.
    Wideroff L, Vaughan TL, Farin FM, Gammon MD, Risch H, Stanford JL, et al. GST, NAT1, CYP1A1 polymorphisms and risk of esophageal and gastric adenocarcinomas. Cancer Detect Prev. 2007;31:233–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Suzuki S, Muroishi Y, Nakanishi I, Oda Y. Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer. J Gastroenterol. 2004;39:220–30.CrossRefPubMedGoogle Scholar
  29. 29.
    Zendehdel K, Bahmanyar S, McCarthy S, Nyren O, Andersson B, Ye W. Genetic polymorphisms of glutathione S-transferase genes GSTP1, GSTM1, and GSTT1 and risk of esophageal and gastric cardia cancers. Cancer Causes Control. 2009;20:2031–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Hong SH, Kim JW, Kim HG, Park IK, Ryoo JW, Lee CH, et al. Glutathione S-transferases (GSTM1, GSTT1 and GSTP1) and N-acetyltransferase 2 polymorphisms and the risk of gastric cancer. J Prev Med Public Health. 2006;39:135–40.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2010

Authors and Affiliations

  • Ya-ping Luo
    • 1
  • Han-chun Chen
    • 1
  • Md. Asaduzzaman Khan
    • 1
  • Fang-zhi Chen
    • 2
  • Xin-xing Wan
    • 1
  • Bo Tan
    • 1
  • Fang-dan Ou-Yang
    • 1
  • Dian-zheng Zhang
    • 1
    • 3
  1. 1.Department of Biochemistry, School of Biological Science and TechnologyCentral South UniversityChangshaChina
  2. 2.Department of Urology, Second Xiangya HospitalCentral South UniversityChangshaChina
  3. 3.Department of Biochemistry/Molecular BiologyPhiladelphia College of Osteopathic MedicinePhiladelphiaUSA

Personalised recommendations